A comprehensive view of Vir Biotechnology Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

GSK and Vir Biotechnology announce US government agreement to purchase an additional 600,000 doses of sotrovimab, an investigational monoclonal antibody for early treatment of COVID-19; doses will be delivered throughout Q1 2022
Published: January 12, 2022 by GlaxoSmithKline PLC
GSK and Vir Biotechnology announces marketing authorization in Europe for intravenous Xevudy as an early treatment for COVID-19 in patients at risk of progressing to severe illness
Published: December 17, 2021 by GlaxoSmithKline PLC
GSK and Vir Biotechnology announce new preclinical findings showing sotrovimab retains activity against the Omicron variant of COVID-19
Published: December 07, 2021 by GlaxoSmithKline PLC
GSK and Vir Biotechnology announce conditional authorization in the UK for Xevudy injection for treatment of COVID-19 patients at risk of severe illness
Published: December 02, 2021 by GlaxoSmithKline PLC
GSK and Vir Biotechnology announce contracts totaling US$1B with US government to supply sotrovimab, an investigational antibody treatment for COVID-19; GSK will supply doses by Dec. 17, 2021
Published: November 17, 2021 by GlaxoSmithKline PLC

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count